Rare diseases
Investigational molecules
Locations
BLU-808 is an investigational substance that is currently being studied in clinical research. It has not been described as an authorised medicine in the available registry data, and no trade names or other development codes are listed for it. The substance is being evaluated in a Phase 2 clinical trial for the treatment of chronic urticaria, a condition characterised by recurrent itchy wheals, angioedema, or both.[1]
The available registry data do not describe the mechanism of action of BLU-808. No information is provided about the molecular target, the pathway affected, or the pharmacological class to which the substance belongs. The trial record focuses on the safety and tolerability of the substance rather than on its mechanism.[1]
The registered trial investigates BLU-808 in two related conditions:
Both conditions fall under the broader category of chronic urticaria, which can significantly affect quality of life.[1]
BLU-808 is administered as a tablet taken by mouth. The trial interventions list BLU-808 tablets at two dose levels, both recorded as 0 mg in the registry, which means the specific doses were not reported in the public record. A placebo tablet matching BLU-808 is used as the comparison arm in the study.[1]
One clinical trial of BLU-808 is registered. The study, identified as NCT06931405, is a Phase 2 interventional trial with a planned enrolment of 150 participants. It is currently authorised, meaning the trial has received regulatory approval to proceed but is not yet recruiting.[1]
The trial is divided into two parts, Part A and Part B, both of which aim to characterise the safety and tolerability of BLU-808. The primary outcome measure is the overall safety profile, assessed by the type, frequency, severity, and causality of adverse events. This means the study is designed first to establish how well the substance is tolerated before any broader efficacy testing is undertaken.[1]
The study includes both chronic inducible urticaria and chronic spontaneous urticaria, although the registry record does not specify separate enrolment targets for each condition. The comparison arm receives a placebo tablet, allowing the safety data for BLU-808 to be compared against an inactive treatment.[1]
The registry record for the trial does not list specific side effects of BLU-808. The primary objective of the ongoing Phase 2 study is to characterise the safety profile of the substance, including the type, frequency, severity, and causality of adverse events. Once the trial results are reported, they are expected to provide the first systematic information on side effects associated with BLU-808.[1]
Each condition opens its own overview and trial list
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.
